Trachyspermum ammi Linn. (T. ammi) is an aromatic, grassy, annual plant belonging to Umbelliferae family which grows in the east of India, Pakistan, Iran, and Egypt. T. ammi has been used traditionally to treat arthritis, colic, diarrhea and gastrointestinal problems. In addition to these medicinal uses, T. ammi continues to be valued around the world as an important cooking spice and is believed to relief the common cold, flu-like symptoms, headaches, and even painful menstrual periods. These multiple uses can be explained by its several active compounds. The phytochemical studies on T. ammi seeds have revealed the presence of alkaloids, steroids, fixed oils, glycosides, tannins, saponin and flavonoids, cumene, thymene, amino acids and dietary fiber essential oils like thymol, c-terpinene, p-cymene. Several pharmacological studies on anti-tussive effect, inhibitory effect on histamine (H1) receptors, antihypertensive, antispasmodic, bronchodilator, hepato-protective, analgesic, anti-inflammatory, antioxidant and anti mutagenic activities of T. ammi seed extracts have been reported in the literature. The present review is therefore, an effort to give a detailed survey of the literature on traditional, phytochemical and pharmacological properties of T. ammi.

Background: and Purpose There are reports of decline in the rates of acute emergency presentations during coronavirus disease 2019 (COVID-19) pandemic including stroke. We performed a meta-analysis of the impact of COVID-19 pandemic on rates of stroke presentations and on rates of reperfusion therapy. Methods: Following the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines, we systematically searched the literature for studies reporting changes in stroke presentations and treatment rates before and during the COVID-19 pandemic. Aggregated data were pooled using meta-analysis with random-effect models. Results: We identified 37 observational studies (n=375,657). Pooled analysis showed decline in rates of all strokes (26.0%; 95% confidence interval [CI], 22.4 to 29.7) and its subtypes; ischemic (25.3%; 95% CI, 21.0 to 30.0), hemorrhagic (27.6%; 95% CI, 20.4 to 35.5), transient ischemic attacks (41.9%; 95% CI, 34.8 to 49.3), and stroke mimics (45.6%; 95% CI, 33.5 to 58.0) during months of pandemic compared with the pre-pandemic period. The decline was most evident for mild symptoms (40% mild vs. 25%–29% moderate/severe). Although rates of intravenous thrombolytic (IVT) and endovascular thrombectomy (EVT) decreased during pandemic, the likelihood of being treated with IVT and EVT did not differ between the two periods, both in primary and in comprehensive stroke centers (odds ratio [OR], 1.08; 95% CI, 0.94 to 1.24 and OR, 0.95; 95% CI, 0.83 to 1.09, respectively). Conclusions Rates of all strokes types decreased significantly during pandemic. It is of paramount importance that general population should be educated to seek medical care immediately for stroke-like symptoms during COVID-19 pandemic. Whether delay in initiation of secondary prevention would affect eventual stroke outcomes in the long run needs further study.